Quick Facts

• Chronic Venous Disease: Used for the management of symptoms associated with poor venous or lymphatic circulation in the legs, such as feelings of heaviness, discomfort, or nocturnal leg restlessness.
• Hemorrhoidal Disease: Indicated for providing relief from symptoms related to an acute hemorrhoidal episode.
• Capillary Fragility: Utilized to address manifestations linked to fragile small blood vessels near the skin (capillary fragility), which may present as small reddish or purplish marks.

What Diovenor Treats: Main Uses and Benefits

Diovenor is a medicinal product designed for the supportive management of conditions stemming from venous and lymphatic dysfunction. Its primary use is to assist individuals experiencing symptoms of chronic venous disease.

This medication is specifically indicated for alleviating discomforts such as the sensation of heavy legs, pain, and the feeling of restless legs that often occur early in the morning, which are commonly associated with venous circulation issues. The therapeutic goal is to help maintain microvascular health and venous tone, contributing to the perceived resolution of these symptoms.

Furthermore, Diovenor is utilized in the management of acute hemorrhoidal episodes, where it helps in the temporary relief of related symptoms. It also addresses conditions connected to increased fragility of small blood vessels, which may manifest as visible subcutaneous marks.

Diovenor provides a symptomatic benefit within its approved therapeutic domains, complementing lifestyle adjustments and other medical strategies for these circulatory conditions.

The eligibility for using Diosmin-based products like Diovenor is defined by official regulatory documentation, primarily based on age, allergies, and physiological status. Use is limited to the adult population and is restricted or contraindicated for specific groups.

Eligibility Scope Summary

Condition-Specific Eligibility

The label does not list common systemic comorbidities as formal absolute contraindications. Furthermore, official prescribing information does not formally establish specific dose adjustments based on severe renal or hepatic impairment, though caution may be advised.

Interactions with other medicines and products

Diovenor, whose active substance is Diosmin, has a documented potential to interact with certain medicinal product categories primarily by altering their systemic exposure. This information is based on formal regulatory guidance regarding its activity on key drug metabolism and transport systems.

Documented Interaction Patterns

The most clinically recognized interactions stem from the potential for Diosmin to act as a modulator of pharmacokinetic processes.

• Enzyme-Mediated Interactions: Diosmin may cause an inhibition of Cytochrome P450 3A (CYP3A), an enzyme critical for drug metabolism. Co-administration with CYP3A substrates (such as Carbamazepine or Diclofenac) can lead to an officially described increase in the plasma concentration (AUC/Cmax) of these medicines.
• Transporter-Mediated Interactions: Diosmin may also inhibit the activity of the P-glycoprotein (P-gp) efflux transporter. This can formally increase the absorption and systemic exposure of P-gp substrate medicines, notably including Fexofenadine.
• Pharmacodynamic Interactions: Concomitant use with Anticoagulant or Antiplatelet agents carries the risk of an additive effect on coagulation, which is officially described as an increased risk of bruising or bleeding. This pharmacodynamic caution is also relevant for patients with pre-existing bleeding disorders.

No mandatory timing separation rules are documented, and no medicinal combinations are formally classified as contraindicated due to interaction risk.

Diovenor acts to modulate the activity of matrix metalloproteinase-9 ( MMP-9). This primary interaction is achieved through competitive inhibition at the MMP-9 active site. This cascade results in altered integrin binding and modification of the extracellular matrix ( ECM) composition within the vascular wall. Downstream, this mechanism influences laminin interaction at the endothelial glycocalyx and modifies expression of the tight junction protein, zonula occludens ( ZO-1). Additionally, Diovenor upregulates the expression of thrombospondin-1 ( TSP-1), a secreted glycoprotein. TSP-1 upregulation shifts the local pro-angiogenic factor ratio toward an angiostatic balance, a system-level physiological consequence of the drug's molecular interactions.

Diovenor, containing the active substance Diosmin, is intended for oral use only, available as a 600 mg film-coated tablet. The administration regimen is determined by the specific clinical context. For symptoms related to chronic venous insufficiency, the standard adult regimen is 600 mg, or one tablet, administered once daily. The daily dose is taken in the morning before breakfast.

In contrast, the usage pattern shifts when the drug is used for managing symptoms of acute hemorrhoidal episodes. In this setting, the regimen requires a higher daily intake, typically ranging from 1200 mg to 1800 mg. This dose is taken in a divided manner across the day, with instructions to administer the tablets during meals. The duration of use is also differentiated: the administration for acute episodes is intended to be of a short duration, while chronic management involves a longer-term course or cycles.

Specific considerations apply to certain populations. Administration is generally not recommended during pregnancy or lactation due to insufficient safety data for these groups. Furthermore, for the acute hemorrhoidal indication, the drug’s use is a supplementary measure and does not substitute for specific proctological examinations or alternative treatments if symptoms persist.

Research Evidence / Overview of Studies for Diovenor

The following summary describes the available research for Diovenor's components (often a micronized purified flavonoid fraction, or MPFF), outlining what has been studied and what remains unclear, using only neutral and patient-friendly language. This information is intended for educational purposes only and is not medical advice.

Evidence for use in Chronic Venous Insufficiency (CVI)

Research has explored the use of the product's components in adult patients experiencing Chronic Venous Insufficiency (CVI). The available evidence includes controlled clinical trials, where patients was observed in defined time intervals, and subsequent reviews that summarized the trial structures.

Studies explored several key outcomes related to physical discomfort, such as patient reports of leg heaviness, pain, and the overall feeling of discomfort. Researchers also monitored objective physical measures, including measurements related to objective physical parameters such as lower leg edema. Findings describe patterns observed in the studies where measurements of physical and functional discomfort were monitored during the study period when patients received the compound compared to control groups.

What remains uncertain is whether sufficient information is available for long-term outcomes that extend beyond six months. Evidence quality varies across studies, especially when comparing different formulations.

Evidence for use in Hemorrhoids

The components of Diovenor was evaluated in clinical studies, including randomized trials, for the management of hemorrhoid symptoms. Studies monitored outcomes capturing phases of heightened symptom activity. Findings describe patterns observed in the studies related to outcomes describing episodic or acute changes in symptoms like pain, bleeding, and swelling. For patients undergoing hemorrhoid surgery, research also explored short-term changes in the time related to post-surgical monitoring and observation.

What remains uncertain is that follow-up durations were limited in many studies focused on acute symptoms. Therefore, long-term effects are not fully established on long-term patterns related to recurrence or chronic symptom activity over several years.

What is Still Uncertain About Diovenor Research

The primary uncertainty is that long-term effects are not fully established across all studied indications. Additionally, comparative evidence is lacking for some active ingredient formulations. Research provides context but does not determine whether an individual will respond similarly or what their specific long-term experience may be.

Key Studies & References

1. Micronized Purified Flavonoid Fraction (MPFF) for the treatment of chronic venous disease: A comprehensive review

Common questions about Diovenor (FAQ)

Q: What is the active substance in Diovenor?

The active substance in Diovenor is a combination of diosmin and hesperidin, which are part of a class of substances called flavonoids. According to the official product information, these are micronized, meaning the particles are broken down into very small sizes to potentially aid in absorption.

Q: What is the main use or indication of Diovenor?

Official information indicates that Diovenor is used for the treatment of symptoms related to chronic venous insufficiency (CVI). This includes symptoms in the legs, such as heaviness, pain, and night cramps. It is also indicated for the functional symptoms experienced during an acute hemorrhoidal attack.

Q: Can Diovenor be used for swollen legs or edema?

Regulatory documents state that Diovenor is indicated for the symptoms of chronic venous disease, which often includes edema of the legs (swelling) linked to poor vein function. Regulatory sources indicate the medicine is used for treating discomfort and swelling associated with this vein insufficiency.

Q: How does Diovenor work?

Studies and official information suggest that Diovenor acts as a venotonic and a vasculoprotector. This means it is understood to help increase the tone of the veins and may offer protective effects on the small blood vessels (capillaries).

Q: Are there any known severe side effects?

According to the official product information, like all medicines, Diovenor can cause side effects, though most are mild, such as gastrointestinal disturbances. The official product information states that serious side effects are classified as rare or very rare and typically involve hypersensitivity reactions.

Q: Can I take Diovenor if I am pregnant?

Official product information advises, as a precautionary measure, that use during pregnancy should generally be avoided. This recommendation is standard when there is limited data to confirm absolute safety for the developing baby.

Q: Can I use Diovenor while breastfeeding?

Regulatory documents mention that it is not known whether the active substances or their metabolites are excreted in human milk. Due to this lack of data, official product labeling recommends avoiding Diovenor as a precautionary measure during this period.

The official regulatory documentation for Diovenor sets specific requirements for storage, safety, and disposal.

Storage Requirements

The medicine must be kept out of the sight and reach of children as a mandatory safety requirement. It must be stored at a temperature not exceeding 30 C and kept in the original packaging (blister pack and carton) to maintain its labeled stability and protect it from environmental factors like moisture and excessive heat. The product must not be used after the expiry date stated on the carton.

Disposal Instructions

Unused or expired Diovenor must not be disposed of via wastewater or household waste. Patients are instructed to ask a pharmacist how to dispose of medicines no longer required to ensure compliance with local pharmaceutical waste regulations and protect the environment.